0.87
-8.03%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Qlife Holding
Its shares trade on Nasdaq Stockholm under the ticker QLIFE.ST. It has been listed since 2 March 2020. In the fiscal year to 31 December 2025, it reported revenue of SEK 324,000 and a net loss of SEK 20.6m. At that date it held total assets of SEK 9.6m and shareholders' equity of −SEK 7.5m.
Qlife Holding AB is medical technology company, which engages in the development, manufacture, and marketing of medical technology products and devices. The company is headquartered in Helsingborg, Skane. The company went IPO on 2020-03-02. Egoo performs analyzes that correlate to over 99 percent with high-performance laboratory instruments. The Egoo instrument measures biomarkers for the chronic diseases Phenylketonuria (PKU), rheumatoid arthritis (RA) and cancer. Qlife Holding is the parent company of the wholly owned Danish medical technology subsidiary Qlife ApS. Qlife ApS develops a medical technology product with the long-term goal of giving people access to safe and valid biomarker data at home.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 2 Mar 2020
- Website
- qlifeholding.com ↗
Leadership
Pay as last reported
- Thomas WarthoeChief Executive Officer & Director, since 2019
- Henrik LjungCo-Chief Financial Officer, since 2020
- Lars BangsgaardCo-Chief Financial Officer, since 2019
- Peter WarthoeChief Scientific Officer, since 2019
- Ebbe FindingChief Technology Officer, since 2019
- Jakob Broberg LindGlobal Sales Director, since 2020
- Mette GrossChairman, since 2019
- Thomas WarthoeChief Executive Officer & Director, since 2020
- Mette-Marie Harild, EMBAIndependent Director, since 2021
- Ulrik Harrysson, MBAIndependent Director, since 2021
- Mikael PerssonIndependent Director, since 2021
- John MollIndependent Director, since 2019
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Egoo correlates to over 99 percent with high-performance laboratory instruments.
- Qlife ApS develops home biomarker testing for chronic diseases PKU, RA, and cancer.
- Qlife Holding AB is a medical technology company with a strong Health Care sector focus.
Weaknesses
- Qlife ApS is a wholly owned Danish subsidiary with limited market presence.
- The company's IPO occurred on 2 March 2020, indicating recent market entry.
- Egoo instrument measures biomarkers for specific chronic diseases only.
Opportunities
- Expanding home biomarker testing to new chronic diseases beyond PKU, RA, and cancer.
- Growing demand for home health monitoring in the Health Care sector.
- Potential partnerships with healthcare providers in Sweden and Denmark.
Threats
- Competition from established medical technology companies in the Health Care sector.
- Regulatory changes affecting medical device approvals in Sweden and Denmark.
- Economic downturns impacting healthcare spending in the Health Care industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.